Ruxolitinib(J01-901)

Ruxolitinib(J01-901)

  • $83.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :JAK1 and 2 Inhibitor

Species :

Tag :

Expression System:

Sequence :

CAS Registry Number :941678-49-5

Molecular Formula :C17H18N6

Appearance :White powder

Molecular Weight :306.4

Purity :>98% (HPLC,TLC); NMR (conforms)

Solubilization :May be dissolved in DMSO (28 mg/ml) or ethanol (15 mg/ml warm)

Aliases :(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

Storage and Stability :Store desiccated as supplied at -20oC for up to 2 year. Store solutions at -20oC for up to 3 months.

Scientific Background :Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively1. Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM)2. Inhibits the proinflammatory secretome of senescent cells3. The JAK1 S646P mutant is highly sensitive to ruxolitinib4. Clinically useful anticancer agent.

References :
1. S Verstovsek et al. Hematol. Am. Soc. Hematol. Educ. Program 2009 2009(1)636

2. A Quintas-Cardama et al. Blood 2010 115:3109

3. JN Farr et al. Nat. Med. 2017 23:1072

4. Q Li et al. Oncotarget 2017 8:34687

References :
1. S Verstovsek et al. Hematol. Am. Soc. Hematol. Educ. Program 2009 2009(1)636

2. A Quintas-Cardama et al. Blood 2010 115:3109

3. JN Farr et al. Nat. Med. 2017 23:1072

4. Q Li et al. Oncotarget 2017 8:34687

Molecular Structure :

Product Sheets (By Lot #) :

D3905-2.pdf

Research Areas :Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway